Certolizumab Pegol for Psoriasis and Psoriatic Arthritis

[1] Gottlieb AB(2005)TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques J Immunol 175 2721-2729

[2] Chamian F(2014)Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol BioDrugs. 28 15-23

[3] Masud S(2002)Formatting antibody fragments to mediate specific therapeutic functions Biochem Soc Trans 30 512-516

[4] Cardinale I(2007)Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents Inflamm Bowel Dis 13 1323-1332

[5] Abello MV(2015)Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn’s disease Expert Opin Drug Metab Toxicol 11 317-327

[6] Lowes MA(2008)The impact of PEGylation on biological therapies BioDrugs. 22 315-329

[7] Pasut G(2018)Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2) J Am Acad Dermatol 79 302-314.e6

[8] Weir ANC(2018)Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT) J Am Acad Dermatol 79 266-276.e5

[9] Nesbitt A(2019)Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials J Eur Acad Dermatol Venereol 33 546-552

[10] Chapman AP(2012)Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension Br J Dermatol 167 180-190

[1] Gottlieb AB(2005)TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques J Immunol 175 2721-2729

[2] Chamian F(2014)Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol BioDrugs. 28 15-23

[3] Masud S(2002)Formatting antibody fragments to mediate specific therapeutic functions Biochem Soc Trans 30 512-516

[4] Cardinale I(2007)Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents Inflamm Bowel Dis 13 1323-1332

[5] Abello MV(2015)Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn’s disease Expert Opin Drug Metab Toxicol 11 317-327

[6] Lowes MA(2008)The impact of PEGylation on biological therapies BioDrugs. 22 315-329

[7] Pasut G(2018)Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2) J Am Acad Dermatol 79 302-314.e6

[8] Weir ANC(2018)Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT) J Am Acad Dermatol 79 266-276.e5

[9] Nesbitt A(2019)Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials J Eur Acad Dermatol Venereol 33 546-552

[10] Chapman AP(2012)Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension Br J Dermatol 167 180-190